Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Local delivery of novel MRTF/SRFinhibitors prevents scar tissue formation in a preclinical model of fibrosis
Nurmemmedov E
1-3H3/b11-6+
(S)-(-)-Bay-K-8644
Smiles: OC1C=C(O)C(=C2OC(=CC(=O)C=12)C1C=CC(O)=CC=1)C1=CC(=CC=C1O)C1=CC(=O)C2=C(C=C(O)C=C2O)O1
MK-0354 497 Local delivery of novel MRTF/SRFinhibitorsMK 0354 is a partial agonist of GPR109a receptor, for hGPR109a mGPR109a with EC50 of 1. 65 1. 08 M, showed no activation of GPR109b. IC50 value: 1. 65 M (EC50, for hGPR109a), 1. 08 M (EC50, for mGPR109a) Target: GPR109ain vitro: MK 0354 demonstrated clear and statistically significant partial agonism in the cAMP assays for both the mouse and human receptors with efficacy approximately 60 70% of that of either nicotinic acid or hydroxy butyrate, a
US$ 39.00
US$ 115.50
US$ 93.00
US$ 35.00